Innate shows Bicycle the path for Nectin-4
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
Jabez heads for the clinic
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
Pfizer drops its B7-H4 conjugate
Felmetatug vedotin’s exit could be bad news for Mersana.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
